ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0397

Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis

Patrícia Martins1, Eduardo Dourado1, João Eurico Fonseca1, Vasco C Romão1 and Catarina Resende2, 1Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, 2Centro Hospitalar Universitário Lisboa Norte, Rheumatology Department, Lisbon, Portugal

Meeting: ACR Convergence 2021

Keywords: iloprost treatment, Systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Session Title: Systemic Sclerosis & Related Disorders – Clinical Poster I (0387–0413)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Vasculopathy is a crucial feature of systemic sclerosis (SSc). Raynaud’s phenomenon (RP) and digital ulcers (DU) greatly impact the patients’ quality of life. Intravenous (IV) iloprost is broadly used to treat RP and DU secondary to SSc. However, no internationally accepted standardised protocol on iloprost use is currently available.

Methods: We reviewed the clinical records of patients with SSc-related DU and/or moderate-to-severe RP (more than two attacks/day with at least moderate pain) not responsive to calcium channel blockers (CCB), receiving or that have received IV iloprost infusions from January 1st 2011 to March 31st 2021. There were no restrictions concerning combination treatments or comorbidities. Our protocol for IV iloprost consists of an initial ten-hour infusion of iloprost 200ng/mL (0.05 mg in 250 ml of 0.9% saline solution) on five consecutive days, followed by a single-day infusion every month. Over the ten hours of infusion, there is a progressive increase of the dose, up to the patient’s maximum tolerated dose, ranging from 0.5 to 1.5 ng/kg/min. The infusion rate starts at 4 ml/h and is increased according to the following scheme: 4 mL/h (1st hour), 8 mL/h (2nd hour), 12 mL/h (3rdhour), and then 16 mL/h if tolerated by the patient, until the end of the infusion. Adverse events were assessed by consulting clinical records.

Results: Forty-nine patients with SSc have been treated with IV iloprost according to our treatment protocol. Patients’ characteristics and clinical features are presented in Table 1. Thirty patients initiated iloprost to treat DUs, 14 to treat RP and 5 to treat both. Sixty per cent of patients in the DU group resolved the DUs within the first month of therapy. RP significantly improved in 64% of patients in the RP group within a month. In the RP+DU group, 60% of patients resolved the DUs and significantly improved RP after three months. Currently, 36 patients are actively undergoing treatment. The reasons for discontinuation in the remaining 13 patients included clinical improvement (N=5), switch to treatment with ambulatory elastomeric pump (N=4), death (N=3) or change of follow-up to another hospital (N=1). Iloprost persistence at two and five years after treatment onset was 95.9% and 83.7% (Figure 1), respectively. Nine adverse events were recorded (18.4% of patients): headache was reported in four patients, hypotension in three patients, tachycardia in one patient and generalised erythroderma in one patient.

Conclusion: SSc patients achieved clinical improvement with a good tolerability profile, leading to a high drug persistence rate. Side effects were managed by adapting the infusion rate. Our data support that monthly single iloprostinfusions can be effective, safely administered and adjusted according to the drug tolerance.


Disclosures: P. Martins, None; E. Dourado, None; J. Fonseca, None; V. Romão, None; C. Resende, None.

To cite this abstract in AMA style:

Martins P, Dourado E, Fonseca J, Romão V, Resende C. Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/safety-and-persistence-of-monthly-intravenous-iloprost-in-systemic-sclerosis/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-persistence-of-monthly-intravenous-iloprost-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences